# An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma

> **NCT01368276** · PHASE3 · COMPLETED · sponsor: **BioVex Limited** · enrollment: 31 (actual)

## Conditions studied

- Melanoma

## Interventions

- **BIOLOGICAL:** Talimogene Laherparepvec
- **DRUG:** Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF)

## Key facts

- **NCT ID:** NCT01368276
- **Lead sponsor:** BioVex Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2014-09
- **Final completion:** 2014-09
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2015-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01368276

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01368276, "An Extended Use Study of Safety and Efficacy of Talimogene Laherparepvec in Melanoma". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01368276. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*